ADVFN - Advanced Financial Network.
HOME» NYSE » M » MRK Stock Price » MRK Stock News

Merck Share News

 Merck & Co., Stock Price
MRK Stock Price
 Merck & Co., Stock Chart
MRK Stock Chart
 Merck & Co., Stock News
MRK Stock News
 Merck & Co., Company Information
MRK Company Information
 Merck & Co., Stock Trades
MRK Stock Trades

Bristol-Myers Gets SEC Subpoena In Foreign Bribery Probe

By Peter Loftus Of DOW JONES NEWSWIRES Drug maker Bristol-Myers Squibb Co. (BMY) said it has received a subpoena from the U.S. Securities and Exchange Commission as part of an investigation into bribery overseas. Bristol-Myers said the subpoena received in March seeks information related to sales and marketing practices in "various countries." The New York-based company said in a quarterly report filed Thursday with the SEC that it was cooperating with the government. A spokeswoman declined comment beyond the information in Thursday's SEC filing. Bristol-Myers, which sells the anti-clotting drug Plavix, previously disclosed that the SEC was investigating the activities of the company's units in Germany, concerning potential violations of the U.S. Foreign Corrupt Practices Act, or FCPA. U.S. authorities in recent years have stepped up enforcement of the FCPA, which bars U.S. companies from bribing foreign officials to obtain or retain business. Multinational drug and medical-device makers based in the U.S. have been among the targets of enforcement. Last year, Johnson & Johnson (JNJ) agreed to pay nearly $80 million to resolve allegations that it paid bribes to doctors in three European countries, as well as kickbacks to Iraq to illegally obtain business under former leader Saddam Hussein. Other drug makers--including Pfizer Inc. (PFE), Merck & Co. (MRK) and Eli Lilly & Co. (LLY)--also have been the subjects of federal inquiries regarding the FCPA. -By Peter Loftus, Dow Jones Newswires; +1-215-982-5581; peter.loftus@dowjones.com

Stock News for Merck (MRK)
DateTimeHeadline
05/24/201614:35:00Merck Announces Third-Quarter 2016 Dividend
05/24/201613:31:00MSD Animal Health riceve l'approvazione all'immissione in commercio...
05/24/201612:21:00MSD Animal Health erhält Marktzulassung der Europäischen Arzneimittelagentur f...
05/24/201609:20:00MSD Animal Health reçoit une autorisation de commercialisation...
05/24/201608:00:00Merck to Present at the UBS Global Healthcare Conference
05/24/201606:19:00MSD Animal Health Receives Marketing Approval from European Medicines...
05/23/201616:40:00Samsung Targets U.S. Drug Market With Remicade Knockoff
05/23/201609:00:00Merck Foundation Announces the Alliance to Advance Patient-Centered...
05/20/201614:35:51Statement of Changes in Beneficial Ownership (4)
05/19/201616:20:00Germany's Bayer Breaks With Caution in Monsanto Bid
05/18/201622:27:00New Hope for Melanoma Patients -- Update
05/18/201617:29:00New Hope for Melanoma Patients
05/18/201617:19:00New KEYTRUDA® (pembrolizumab) Data from KEYNOTE-006 & KEYNOTE-001...
05/16/201608:00:00New KEYTRUDA® (pembrolizumab) Data at 2016 ASCO Annual Meeting...
05/12/201611:41:25Statement of Changes in Beneficial Ownership (4)
05/12/201611:41:25Statement of Changes in Beneficial Ownership (4)
05/12/201611:41:25Statement of Changes in Beneficial Ownership (4)
05/12/201611:41:25Statement of Changes in Beneficial Ownership (4)
05/12/201611:41:25Statement of Changes in Beneficial Ownership (4)
05/12/201611:41:25Statement of Changes in Beneficial Ownership (4)

Merck and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2015 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad